PI Training

Question 1

Dosage forms and strengths

Answer 1

Section 3

Question 2

Post marketing experience

Answer 2

Section 6.2

Question 3

Local Nasal Effects

Answer 3

Section 5.2

Question 4

Warnings and precautions

Answer 4

Section 5

Question 5

Hypothalamic-pituitary-adrenal HPA Axis effects

Answer 5

Section 5.5

Question 6

Dosing information

Answer 6

Section 2.1

Question 7

Clinical Trials Experience

Answer 7

Section 6.1

Question 8

Important Administration Instructions

Answer 8

Section 2.2

Question 9

Cytochrome P450 3A4

Answer 9

Section 7.2

Question 10

Use in specific populations

Answer 10

Section 8

Question 11

Warnings and Precautions

Answer 11

Section 5

Question 12

Glaucoma and cataracts

Answer 12

Section 5.3

Question 13

Use of Cytochrome P450 3A4 inhibitors

Answer 13

Section 5.6

Question 14

Effect on Growth

Answer 14

Section 5.7

Question 15

Drug interactions

Answer 15

Section 7

Question 16

Pediatric Use

Answer 16

Section 8.4

Question 17

Central nervous system depressants

Answer 17

Section 7.1

Question 18

Geriatric Use

Answer 18

Section 8.5

Question 19

Pregnancy

Answer 19

Section 8.1

Question 20

Adverse reactions

Answer 20

Section 6

Question 21

Overdosage

Answer 21

Section 10

Question 22

Clinical Pharmacology

Answer 22

Section 12

Question 23

Mechanism of Action

Answer 23

Section 12.1

Question 24

Carcinogenesis mutagenesis impairment of fertility

Answer 24

Section 13.1

Question 25

Description

Answer 25

Section 11

Question 26

How supplied/storage and handling

Answer 26

Section 16

Question 27

Pharmacodynamics

Answer 27

Section 12.2

Question 28

Clinical Studies

Answer 28

Section 14

Question 29

Seasonal Allergic Rhinitis

Answer 29

Section 1.1

Question 30

Patient counseling information

Answer 30

Section 17

Question 31

Pharmacokinetics

Answer 31

Section 12.3

Question 32

No clinical toxicology

Answer 32

Section 13

Question 33

Somnolence

Answer 33

Section 5.1

Question 34

Nursing Mothers

Answer 34

Section 8.3

Question 35

Immunosuppression

Answer 35

Section 5.4

Question 36

Dosage and administration

Answer 36

Section 2

Question 37

Contraindications

Answer 37

Section 4

Question 38

Indications and Usage

Answer 38

Section 1

Question 39

The recommended dosage of dymista is 1 spray in each nostril twice daily

Answer 39

Section 2.1

Question 41

Dymista should not be r the expiration dat printed in the bottle label of the carton

Answer 41

Section 16

Question 42

Clinical trials of Dymista did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger patients

Answer 42

Section 8.5

Question 44

Dymista nasal spray is formulated as a white, uniform metered-spray suspension for intranasal administration

Answer 44

Section 11

Question 47

In these trials, Dymista demonstrated statistically significant greater decreases in rTNSS as compared to azelastine hydrochloride and to fluticasone propionate, as well as to a placebo

Answer 47

Section 14

Question 48

Each spray delivers a volume of .137mL suspension containing 137mcg of azelastine hydrochloride and 50 mcg of fluticasone propionate

Answer 48

Section 3

Question 49

Dymista contains both azelastine hydrochloride and fluticasone propionate

Answer 49

Section 12.1

Question 51

Dymista nasal spray is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 6 years of age and older who require treatment with both azelastine hydrochloride and fluticasone proprietary for symptomatic relief

Answer 51

Section 1.1

Question 52

When Dymista has not been used for 14 or more days reprime with 1 spray or until a fine mist appears

Answer 52

Section 2.2

Question 54

If I were Health are professional thinking about prescribing Dymista for a youthful patient this section would be helpful when making my prescribing questions

Answer 54

Section 8.4